Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.